We studied preexisting immunity to pandemic (H1N1) 2009 virus in persons in Taiwan. A total of 18 (36%) of 50 elderly adults in Taiwan A s experts were predicting and warning of a new infl uenza pandemic (1), an infl uenza epidemic occurred in April 2009 in the United States and Mexico and resulted in a pandemic 2 months later. The etiologic agent was identifi ed as pandemic (H1N1) 2009 virus. Worldwide, most patients infected with this virus were <25 years of age, and one third of serious cases were in persons <50 years of age (2,3).
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The hemagglutinin gene of pandemic (H1N1) 2009 virus was shown to be derived from the 1918 swine infl uenza virus and contained other genes from human, avian, and swine infl uenza viruses from Eurasia (2) . In this study, we evaluated levels of preexisting cross-reactive antibodies against pandemic (H1N1) 2009 virus produced after previous infection in children and adults in Taiwan. We also examined serologic changes after vaccination with seasonal nonadjuvanted infl uenza vaccine.
The Study
Serum samples were obtained during a nationwide infl uenza vaccine serologic study in Taiwan that started in 2006. Children (<5 years of age), adults (20-49 years of age), older adults (50-74 years of age), and elderly adults (>75 years of age) were recruited. Serum samples were obtained immediately before and 3 weeks after intramuscular injection with 1 dose of nonadjuvanted, trivalent, inactivated infl uenza vaccine formulated for the 2008-09 Northern
Hemisphere winter season (samples were obtained from some participants >75 years of age before and after receiving 1 dose of the vaccine formulated for the 2007-08 winter season).
Microneutralization (MN) and hemagglutination inhibition (HI) assays were performed according to the World Health Organization Manual on Animal Infl uenza Diagnosis and Surveillance (4) . Using these assays with 0.75% guinea pig erythrocytes, we assayed samples for antibodies against A/California/07/2009 (H1N1) virus. Only prevaccination HI assays were conducted for children.
The seroprotection rate was defi ned as the percentage of serum titers >40 by HI or titers >160 by MN. The seroconversion rate was defi ned as the percentage of vaccine recipients whose serum HI titers or MN titers increased by at least 4-fold after vaccination. A p value <0.05 was considered signifi cant. Stata software version 8.2 (StataCorp LP, College Station, TX, USA) was used for analysis.
A total of 176 participants (40 children, 36 adults, 50 older adults, and 50 elderly adults) were enrolled (Table) . Few or no preexisting cross-reactive antibodies against pandemic (H1N1) 2009 virus were detected by HI assay in samples from children (prevaccination seroprotection rate 0%). As age increased, prevaccination seroprotection rates became higher for HI and MN assays. After vaccination, seroprotection rates and geometric mean titers measured by HI assay were essentially unchanged but increased significantly in the 3 adult groups when measured by MN assay (p<0.05). Seroconversion rates among all participants were low. Analyses of relationships between age and antibody titers are shown in the Figure. We log-transformed MN and HI titers, and used multiple regression, controlling for age groups to analyze the correlation between age and titer. Doubling of HI titers corresponded to an estimated 75% (p<0.01) increment in MN titers adjusted by age. When adjusted for HI titers, MN titers in older adults and elderly adults were 1.74× (p<0.01) and 2× (p<0.01), respectively, those in adults. Older adults and elderly adults with the same HI titers were more likely to have higher MN titers than adults (p<0.05, by ordinal logistic regression analysis).
Conclusions
We found that children in Taiwan had few or no crossreactive antibodies against pandemic (H1N1) 2009 virus. However, adults had some preexisting immunity to this virus. A major fi nding was that 18 (36%) of 50 elderly adults in Taiwan born before 1935 had protective antibodies against currently circulating pandemic (H1N1) 2009 virus. The seroprotection rate may be 50% in persons >80 years of age.
Pandemic (H1N1) 2009 Virus, Taiwan
The MN assay showed that seasonal infl uenza vaccines generated large increases in geometric mean titers in vaccinees in all age groups. We suggest that seasonal infl uenza vaccines are likely to elicit a certain degree of cross-reactive antibodies against pandemic (H1N1) 2009 virus and may provide some level of protection. In persons who had no preexisting seroprotective titers against pandemic (H1N1) 2009 virus, the cross-reactivity produced was not suffi cient to prevent disease; however, it may protect against the severe forms of the disease. Whether elderly persons still have cross-reactivity several decades after exposure to 1918 (H1N1) virus is unknown. The concept of original antigenic sin is a probable explanation. Original antigenic sin has been described in relation to infl uenza virus, dengue virus, HIV, and several other viruses (10) (11) (12) . For persons >65 years of age, the 1918 (H1N1) virus is likely the fi rst infl uenza virus to which they were exposed, and their antibody response should have increased in subsequent years.
Regression analysis showed that older persons with high HI titers were more likely than younger adults to have higher MN titers. Because the HI assay detects only antibodies against hemagglutinin, the MN assay provides more information about the level of protective antibodies against infl uenza viruses. As a person ages, production of antibodies against hemagglutinin or other components of infl uenza virus should protect against potential infections. Although a titer of 40 by HI is accepted as a cutoff value for seroprotection, a consensus for protective titers by MN is lacking (5, 13 
